The purpose of this study is to compare two different lengths of treatment with esomeprazole to see if a shorter treatment period works as well as a longer one in reducing dyspepsia symptoms. Some people in the study will take esomeprazole for seven days, while others will take it for four weeks. The study will measure changes in symptoms using a scoring system called the Glasgow Dyspepsia Severity Score, which tracks how severe the symptoms are over time. The study aims to determine whether the shorter treatment is not worse than the longer treatment, meaning it provides similar relief.

During the study, participants will take esomeprazole by mouth according to their assigned treatment schedule. They will record their symptoms daily so that researchers can track any changes. The maximum daily dose of esomeprazole will be 40 milligrams, and participants may use Rennie as needed for additional symptom relief. The study will last for several weeks, during which time participants will continue to monitor their symptoms. If symptoms do not improve or worsen, participants may be referred for an upper gastrointestinal endoscopy, which is a procedure that allows doctors to look inside the stomach and upper digestive tract using a thin tube with a camera.

Participants in the study will receive either Rikkunshito or a matching placebo, which looks like the treatment but does not contain the active substance. The treatment is administered in the form of granules taken orally. The study will last for a period of up to 16 weeks, during which participants will be monitored to assess the impact of the treatment on their symptoms. The primary focus is to evaluate the therapeutic effect of Rikkunshito on the symptoms of Functional Dyspepsia.

Throughout the study, participants will be asked to keep a daily diary using the Leuven Postprandial Distress Scale (LPDS) to record their symptoms. This will help researchers determine the effectiveness of Rikkunshito compared to the placebo. Additionally, the study will explore how the treatment affects other aspects such as quality of life, anxiety, and depression, using various questionnaires. The goal is to gather comprehensive data on the potential benefits of Rikkunshito for individuals with Functional Dyspepsia.

The purpose of this study is to evaluate how safe almagate is for both the pregnant women and their babies. The study will observe the effects of almagate on the mothers and their babies during pregnancy and after birth. Participants will take almagate for a period of up to 14 days. Throughout the study, doctors will monitor the health of the mothers and their babies, looking at various factors such as the type of delivery, the baby’s weight and length at birth, and the overall health of the newborn. The study will also assess the mothers’ satisfaction with the use of almagate as an antacid.

Participants will have regular follow-up visits with their healthcare providers to discuss their experiences with almagate and any changes in their symptoms. The study aims to provide valuable information on the safety of using almagate during pregnancy, which can help guide future treatment options for pregnant women experiencing heartburn and reflux.

The purpose of the study is to assess how well ALKACITRAT works in relieving symptoms of functional dyspepsia and to ensure it is safe for use. Participants will take the treatment orally, meaning it is swallowed, over a period of time. Throughout the study, researchers will monitor the participants to see if there is an improvement in their symptoms and to check for any side effects.

The study will compare the results between those taking ALKACITRAT and those taking the placebo to determine the treatment’s effectiveness. Researchers will look at changes in the severity of symptoms and overall quality of life. The study will also track any adverse events, which are unexpected medical problems that may occur during the trial. The findings will help in understanding whether ALKACITRAT is a beneficial treatment option for people with functional dyspepsia.

The purpose of the study is to evaluate how effective Roleca Wacholder 100mg is in relieving these digestive symptoms. Participants will take the treatment or placebo orally for a period of up to 12 weeks. Throughout the study, participants will be asked to keep a diary to record their symptoms and any changes they experience. This will help researchers understand how the treatment affects the quality of life of those with dyspeptic digestive complaints.

In addition to assessing the effectiveness of the treatment, the study will also look at how well participants tolerate the treatment and any side effects they might experience. Researchers will also analyze changes in the intestinal microbiome, which is the community of bacteria and other microorganisms living in the gut, before and during the treatment. This information will help determine the safety and overall impact of Roleca Wacholder 100mg on digestive health.

The purpose of the study is to determine which of these methods is most effective in helping patients stop using PPIs while still managing their symptoms. Participants in the study will be randomly assigned to one of the three methods and will be monitored to see how well they do with their assigned method. The study will look at how many people successfully stop using PPIs, how satisfied they are with their treatment, and whether they are willing to continue with the new method. The study will also track how often participants use PPIs during the follow-up period.

This trial is expected to provide valuable information on the best strategies for safely reducing or stopping the use of PPIs in patients who do not have a long-term need for them. The study will run for a set period, and participants will have regular check-ins to assess their progress and any changes in their symptoms. The findings from this study could help improve the way PPIs are prescribed and used in the future, ensuring that patients receive the most appropriate care for their condition.

Participants in the study will receive either the medication Jorveza or a placebo, which is a substance with no active medication. The study will last for a period of 12 weeks, during which participants will take the medication orally in the form of orodispersible tablets, meaning the tablets dissolve in the mouth. The main goal is to observe changes in the number of certain cells called eosinophils in the duodenum, which are often linked to inflammation. Additionally, the study will assess changes in digestive symptoms, quality of life, and other health factors before and after the treatment period.

Throughout the study, participants will be monitored for any changes in their gastrointestinal symptoms, mental health status, and other related health indicators. The study will also look at how the stomach and intestines function, including how quickly the stomach empties and how it responds to being filled. By the end of the study, researchers hope to better understand the potential benefits of using budesonide for treating inflammation associated with Functional Dyspepsia.